CAS: 1195765-45-7; N-(3-(5-(2-Aminopyrimidin-4-yl)-2-(Tert-Butyl)Thiazol-4-yl)-2-Fluorophenyl)-2,6-Difluorobenzenesulfonamide

上下游产品

CAS号1195768-23-0 N-(3-(2-(叔丁基)-5... | CAS号1195768-18-3 2-氟-3-胺基苯甲醚 | CAS号1195768-19-4 达拉菲尼中间体3 | CAS号1042055-86-6 methyl 3-(tert-... | CAS号206551-41-9 3-溴-2-氟苯甲酸甲酯 | CAS号161957-56-8 3-溴-2-氟苯甲酸 | CAS号60230-36-6 2,6-二氟苯磺酰氯 | CAS号1195768-06-9 达帕菲尼甲磺酸盐

达帕菲尼中间体置于ammonium Hydroxide,N-氯代丁二酰亚胺,双氧水,甲基三氧化铼(Vii),Lithium Hexamethyldisilazane体系中,用 四氢呋喃,二氯甲烷,N,N-二甲基乙酰胺,水,乙腈 用作溶剂,化学反应 37.42H,反应生成达帕菲尼
参考文献:通过焓控制的亲核官能化对嘧啶进行 C2 选择性,官能团发散胺化
标题:通过焓控制的亲核官能化对嘧啶进行 C2 选择性,官能团发散胺化
摘要:杂芳胺的合成因其在小分子发现中的重要性而一直是有机化学中的一个重要课题.特别是,2-氨基嘧啶代表了一种在生物活性分子中普遍存在的高度特权结构基序,但通过直接功能化引入嘧啶 C2-N 键的一般策略是难以捉摸的.在这里,我们描述了一种用于位点选择性 C-H 官能化的合成平台,该平台提供嘧啶基亚胺盐中间体,然后可以原位转化为各种胺产物.基于机制的试剂设计允许嘧啶的 C2 选择性胺化,开辟了位点选择性杂芳基 C-H 官能化的新范围.
Doi:10.1021/jacs.1C13373

专利信息

专利号:US-11612610-B2
优先权日:2018-12-14
标题:Mito-magnolol compounds and methods of synthesis and use thereof
发明人：KALYANARAMAN BALARAMAN; ZIELONKA JACEK MICHAL; CHENG GANG; HARDY MICAEL JOËL; OUARI OLIVIER
权利人:MEDICAL COLLEGE WISCONSIN INC; AIX MARSEILLE UNIV; MEDICAL COLLEGE OF WISCONSIN INC
摘要:The present invention provides mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-magnolol compounds in the treatment of cancer, especially anti-cancer therapy or kinase resistant cancers.

专利号:US-2022118094-A1
优先权日:2019-02-21
标题:Synthesis of biomimetic cell wall structure
发明人：WANG YONG; SHI PENG
权利人:PENN STATE RES FOUND
摘要:The present invention relates generally to methods of generating a biomimetic cell wall (BCW) on a target surface, compositions comprising the BCW, and methods of use of the compositions, including biomedical applications of the BCW coated compositions.

专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

专利号:US-2025313551-A1
优先权日:2022-12-15
标题 :Process for the preparation of a quinazolinone derivative
发明人：DOTT PASCAL JEAN CLAUDE; FANTASIA SERENA MARIA; GUILLEMOT-PLASS MAUD; KALDRE DAINIS; LARI GIACOMO MARCO; MODOLO-CHELLAT ISABELLE GEORGETTE HUGUETTE; SEDELMEIER JOERG MATHIAS; TROKOWSKI SEBASTIAN
权利人:HOFFMANN LA ROCHE
摘要:The present invention relates to a new process for the preparation of (3R)—N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide, as well as to a novel intermediate useful for the synthesis of said compound at large scale.

专利号:US-9994550-B2
优先权日:2014-01-07
标题 :Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
发明人：WAGMAN ALLAN S; JOHNSON RUSSELL J; ZAHARIA CRISTIANA A; CAI HAIYING; HU LILY W; DUKE GREG; OHOL-GUPTA YAMINI; HEUER TIMOTHY; O'FARRELL MARIE
权利人:3 V BIOSCIENCES INC
摘要:Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds.

专利号:US-2018140724-A1
优先权日:2015-05-27
标 题:Tumor Deliverable Iron and Protein Synthesis Inhibitors as a New Class of Drugs for the Diagnosis and Treatment of Cancer
发明人：DENG CHANGCHUN; LIPSTEIN MARK; O'CONNOR OWEN A
权利人:DENG CHANGCHUN; LIPSTEIN MARK; OCONNOR OWEN A; UNIV COLUMBIA
摘要:Tumor deliverable iron (TDI) drugs and pharmaceutical compositions and kits comprising them are provided and methods for delivering iron to tumors specifically, either intracellularly or extracellularly. As a result, TDI drugs are useful as a sensitizer for radiation therapy, radio-diagnosis, and chemotherapy, and are of interest. In other embodiments, tumor deliverable protein synthesis inhibitors (TDPSI) are provided and can be delivered to tumors, but not normal cells. These TDPSI drugs and pharmaceutical compositions and kits comprising them are useful for their treatment of cancer, either alone or in combination with other active anti-cancer drugs.